Immune to Cancer: The CRI Blog
-
FDA Approves New LAG-3 Checkpoint Inhibitor Immunotherapy Combination
Patients with unresectable or metastatic melanoma can now be treated with dual checkpoint blockade targeting the PD-1…
-
Cell Therapy Development Lagged in 2020 But Is Gaining Ground Again, New CRI Report Shows
Cell therapy development lagged in 2020, but is gaining ground again, a new CRI report shows.
-
COVID-19’s Impact on Oncology Clinical Trials: A One-Year Follow-Up Analysis
A new CRI report highlights the impact of the COVID-19 pandemic on cancer clinical trials compared to…
-
CRI-Funded Trial Highlights New Hope Against Pancreatic Cancer
New publication from the CRI PRINCE trial highlights benefits of an immunotherapy-chemotherapy combination against advanced pancreatic cancer.
-
Catching Up on Cancer Research with the CRI Anna-Maria Kellen Clinical Accelerator
Through a variety of efforts, the CRI Clinical Accelerator seeks to advance the next generation of immunotherapies…
-
CRI and PICI Collaboration Reveals Path for Improving Personalized Immunotherapies
TESLA initiative scientists identified five keys important for the immune system’s ability to respond against abnormal tumor…
-
How COVID-19 is Impacting Care for Lung Cancer Patients
CRI spoke with Dr. Joshua Sabari about how clinical care for lung cancer patients has been impacted…
-
Defining Resistance to Treatment with Anti-PD-1/PD-L1 Immunotherapy
CRI's Vanessa M. Lucey, Ph.D, MBA, helps guide the design and analysis of future clinical trials involving…
-
Pancreatic Cancer, Immunotherapy, and PRINCE: An Interview with Vanessa Lucey, PhD, MBA
We spoke with Vanessa M. Lucey, PhD, MBA, about challenges of treating pancreatic cancer and promising combination therapy…